151 related articles for article (PubMed ID: 17993505)
1. Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus.
Hegde SS; Reyes N; Skinner R; Difuntorum S
J Antimicrob Chemother; 2008 Jan; 61(1):169-72. PubMed ID: 17993505
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.
Hegde SS; Difuntorum S; Skinner R; Trumbull J; Krause KM
J Antimicrob Chemother; 2009 Apr; 63(4):763-6. PubMed ID: 19155225
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus.
Reyes N; Skinner R; Benton BM; Krause KM; Shelton J; Obedencio GP; Hegde SS
J Antimicrob Chemother; 2006 Aug; 58(2):462-5. PubMed ID: 16735425
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
[TBL] [Abstract][Full Text] [Related]
5. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.
Reyes N; Skinner R; Kaniga K; Krause KM; Shelton J; Obedencio GP; Gough A; Conner M; Hegde SS
Antimicrob Agents Chemother; 2005 Oct; 49(10):4344-6. PubMed ID: 16189117
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
Madrigal AG; Basuino L; Chambers HF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.
Yin LY; Calhoun JH; Thomas TS; Wirtz ED
J Antimicrob Chemother; 2009 Feb; 63(2):357-60. PubMed ID: 19060292
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ME1036 against meticillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of haematogenous pulmonary infection.
Yanagihara K; Ohnishi Y; Morinaga Y; Nakamura S; Kurihara S; Seki M; Izumikawa K; Kakeya H; Yamamoto Y; Yamada Y; Kohno S; Kamihira S
Int J Antimicrob Agents; 2008 Nov; 32(5):401-4. PubMed ID: 18715761
[TBL] [Abstract][Full Text] [Related]
10. Telavancin: in vitro activity against staphylococci in a biofilm model.
Gander S; Kinnaird A; Finch R
J Antimicrob Chemother; 2005 Aug; 56(2):337-43. PubMed ID: 15972312
[TBL] [Abstract][Full Text] [Related]
11. In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan (2006).
Hatano K; Matsuzaki K; Sato Y; Kobayashi I; Yamaguchi K
J Antibiot (Tokyo); 2007 Nov; 60(11):709-12. PubMed ID: 18057701
[TBL] [Abstract][Full Text] [Related]
12. Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
Lubenko IY; Strukova EV; Smirnova MV; Vostrov SN; Portnoy YA; Zinner SH; Firsov AA
J Antimicrob Chemother; 2008 Nov; 62(5):1065-9. PubMed ID: 18635520
[TBL] [Abstract][Full Text] [Related]
13. Potency of DX-619, a novel des-F(6)-quinolone, in haematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
Yanagihara K; Seki M; Izumikawa K; Higashiyama Y; Miyazaki Y; Hirakata Y; Tomono K; Mizuta Y; Tsukamoto K; Kohno S
Int J Antimicrob Agents; 2006 Sep; 28(3):212-6. PubMed ID: 16887340
[TBL] [Abstract][Full Text] [Related]
14. Telavancin: a novel lipoglycopeptide.
Saravolatz LD; Stein GE; Johnson LB
Clin Infect Dis; 2009 Dec; 49(12):1908-14. PubMed ID: 19911938
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
Hegde SS; Reyes N; Wiens T; Vanasse N; Skinner R; McCullough J; Kaniga K; Pace J; Thomas R; Shaw JP; Obedencio G; Judice JK
Antimicrob Agents Chemother; 2004 Aug; 48(8):3043-50. PubMed ID: 15273119
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
Crandon JL; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2010 Dec; 54(12):5115-9. PubMed ID: 20837760
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.
Thabit AK; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2016 Jan; 60(1):222-8. PubMed ID: 26482306
[TBL] [Abstract][Full Text] [Related]
18. Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.
Lepak AJ; Zhao M; Andes DR
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416551
[TBL] [Abstract][Full Text] [Related]
19. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Stryjewski ME; Graham DR; Wilson SE; O'Riordan W; Young D; Lentnek A; Ross DP; Fowler VG; Hopkins A; Friedland HD; Barriere SL; Kitt MM; Corey GR;
Clin Infect Dis; 2008 Jun; 46(11):1683-93. PubMed ID: 18444791
[TBL] [Abstract][Full Text] [Related]
20. Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.
Nannini EC; Corey GR; Stryjewski ME
Expert Rev Anti Infect Ther; 2012 Aug; 10(8):847-54. PubMed ID: 23030322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]